Genix Pharmaceuticals (GENX) Stock Statistics & Valuation Metrics

Genix Pharmaceuticals has a market cap or net worth of CAD 918.36K. The enterprise value is CAD 1.98M.

Market Cap

CAD 918.36K

Enterprise Value

CAD 1.98M

Genix Pharmaceuticals has 61,224,133 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

61,224,133

Owned by Insiders

3.10%

Owned by Institutions

―

Genix Pharmaceuticals’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.

Return on Equity (ROE)

―

Return on Assets (ROA)

―

Return on Invested Capital (ROIC)

―

Return on Capital Employed (ROCE)

―

Revenue Per Employee

―

Profits Per Employee

―

Employee Count

0

Asset Turnover

―

Inventory Turnover

―

In the last 12 months, Genix Pharmaceuticals had revenue of ― and earned -145.05K in profits. Earnings per share was ―.

Revenue

―

Gross Profit

411.34K

Operating Income

-139.40K

Pretax Income

―

Net Income

-145.05K

EBITDA

-83.22K

Earnings Per Share (EPS)

―

Beta

0.18

52-Week Price Change

-50.00%

50-Day Moving Average

0.02

200-Day Moving Average

0.02

Relative Strength Index (RSI)

30.68

Average Volume (3m)

149.00K

Genix Pharmaceuticals upcoming earnings date is Mar 03, 2027, TBA (Not Confirmed).

Last Earnings Date

Sep 17, 2026

Next Earnings Date

Mar 03, 2027

Ex-Dividend Date

―

Genix Pharmaceuticals has ― in cash and marketable securities with CAD 70.00K in debt, giving a net cash position of ― billion.

Cash & Marketable Securities

―

Total Debt

CAD 70.00K

Net Cash

―

Net Cash Per Share

―

Tangible Book Value Per Share

―

The average price target for Genix Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target

―

Price Target Upside

―

Analyst Consensus

―

Analyst Count

0

Revenue Growth Forecast

-100.00%

EPS Growth Forecast

-233.33%